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The Discovery of Human Herpesvirus 6
(HHV-6)
Initially designated HBLV, for human
B-lymphotropic virus, HHV-6 was isolated
fortuitously in 1986 from interleukin 2-
stimulated peripheral blood mononuclear cells
(PBMCs) of patients with AIDS or
lymphoproliferative disorders (1). The PBMC
cultures exhibited an unusual cytopathic effect
characterized by enlarged balloonlike cells. The
causative agent was identified as a herpesvirus
by electron microscopy and lack of cross-
hybridization to a number of human herpesvi-
ruses (2). The GS strain is the prototype of the
first isolates. Two additional isolates of
lymphotropic human herpesviruses, U1102 and
Gambian, genetically similar to HBLV, were
obtained 1 year later from PBMCs of African
AIDS patients. All of the isolates could grow in T
cells (CEM, H9, Jurkat), in monocytes (HL60,
U937), in glial cells (HED), as well as in B-cell
lines (Raji, RAMOS, L4, WHPT) (3,4). A new
variant, Z29, subsequently shown to differ in
restriction endonuclease pattern from GS-like
strains, was isolated from PBMCs of patients
with AIDS (5). The cells supporting virus growth
were characterized as CD4+ T lymphocytes (6).
The designation HHV-6 was proposed 1 year
after discovery of the first isolate to comply with
the rules established by the International
Committee on Taxonomy of Viruses (7).
More than 100 additional HHV-6 strains
have been isolated from PBMCs of children with
subitum or febrile syndromes (8), from cell-free
saliva of healthy or HIV-infected patients (9,10),
from PBMCs of patients with chronic fatigue
syndrome (CFS) (11), and from PBMCs of
healthy adultsthese PBMCs were cultivated
for human herpesvirus 7 (HHV-7) isolation (12).
The Virus
HHV-6 and HHV-7 belong to the Roseolovirus
genus of the ß-herpesvirus subfamily; HHV-6
species are divided into two variants: HHV-6A
and HHV-6B. The virion particle is 160 nm to 200
nm and has the morphologic features typical of
herpes virion particles (a central core containing
the viral DNA, a 90-nm to 110-nm capsid, and a
tegument layer surrounded by a membrane
structure) (13). We summarize briefly key
features.
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Infections with human herpesvirus 6 (HHV-6), a ß-herpesvirus of which two variant
groups (A and B) are recognized, is very common, approaching 100% in
seroprevalence. Primary infection with HHV-6B causes roseola infantum or exanthem
subitum, a common childhood disease that resolves spontaneously. After primary
infection, the virus replicates in the salivary glands and is shed in saliva, the recognized
route of transmission for variant B strains; it remains latent in lymphocytes and
monocytes and persists at low levels in cells and tissues. Not usually associated with
disease in the immunocompetent, HHV-6 infection is a major cause of opportunistic viral
infections in the immunosuppressed, typically AIDS patients and transplant recipients,
in whom HHV-6 infection/reactivation may culminate in rejection of transplanted organs
and death. Other opportunistic viruses, human cytomegalovirus and HHV-7, also infect
or reactivate in persons at risk. Another disease whose pathogenesis may be correlated
with HHV-6 is multiple sclerosis. Data in favor of and against the correlation are
discussed.354 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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HHV-6A genomes are 159 kbp to 170 kbp
long. As sequenced, the genome of U1102 strain
is 159 kbp long (14); the HHV-6B genome has
been sequenced only partially. Seven gene blocks
in the central region (I-VII) designated as
herpesvirus core genes are common to all
Herpesviridae. Another block, spanning open
reading frames (ORFs) U2 to U14, contains
genes specific to ß-herpesviruses. A further
region, encompassing ORFs U15-U25, contains
genes specific to Roseolovirus genus. Three
genes (U22, U83, U94) are specific to HHV-6 and
absent from HHV-7 (Figure 1). The closest
homology and similarity in genome organization
is to HHV-7 and next to human cytomegalovirus
(HCMV). Amino acid similarity to HHV-7 is
46.6% to 84.9% and to HCMV 41.0% to 75.8%
(14,16). The HHV-6 genome is composed of a
unique sequence (85% to 90% of the genome)
bracketed by direct repeats (10% to 15% of the
genome) that contain the cleavage and
packaging sequences pac-1 and pac-2 and a
single origin of replication (OriLyt) located at 70
kbp of the genome. The number of predicted
ORFs, 102 or 85, varies depending on the values
used to define an ORF and was attributed mainly
Figure 1. Schematic representation of HHV-6 and HHV-7 genomes. The genomes are colinear. Homologies are
46.6% to 84.9%. Red blocks represent the herpesvirus core genes, numbered from I to VII. Yellow blocks
represent ß-herpesvirus subfamily-specific genes (from U2 to U14). Green blocks indicate genes present only in
the Roseolovirus genus, i.e., in HHV-6 and HHV-7. Only three ORFs (U22, U83 and U94) are present in HHV-
6 and absent from HHV-7 (modified from [15]).
on the basis of the similarity with HCMV (14) or
HHV-7 (17) counterparts. Few gene products
have been characterized so far. They include the
immediate-early gene IE-A, which together with
IE-B constitutes the IE locus, a highly spliced
region with an arrangement similar to that of
HCMV (18); the U3 gene, a homolog of the HCMV
UL24 gene, with transactivating activity (19); the
origin binding protein (20), the U53 protease
(21); and p100, also designated p101, highly
immunogenic, and most probably a constituent
of the tegument (22,23). In addition, HHV-6 (but
not HHV-7) carries a homolog of the
adenoassociated type 2 parvovirus rep gene (24),
which is transcribed in latently infected cells
(25). Recently, the U12 protein was recognized as
a ß-chemokine receptor (26). A major focus has
been in the glycoprotein field. Five glycopro-
teins were identified: gB (U39, gp116) (27-30),
gH (U48, gp100) (31), and gL (U82, gp80),
which form at least a heterodimer, gM (U72),
and gp82-105 (U100) (29,30,32,33). gB and gH/
gL were shown to be virion constituents, and
antibody to gH can neutralize virion infectivity
and syncytia formation, suggesting a role of gH
in virus entry and in virus-induced cell fusion
(31). The HHV-6 genome sequence predicts a
locus of glycoproteins U20-U24 and U85 that
are specific to the Roseolovirus genus (14), but
the proteins have not yet been identified. U20
and U85 have a predicted immunoglobulin
structure.
Variant A and Variant B HHV-6 Strains
Frenkel and co-workers (34), Ablashi et al.
(35), and Aubin et al. (36) were the first to355 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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discover that HHV-6 isolates display genetic and
phenotypic variations. All the strains derived so
far segregate into two groups, variant A and
variant B, whose genome organization appears
to be overlapping. Viruses belonging to the two
variants differ with respect to several properties.
Differences in restriction endonuclease cleavage
sites are scattered throughout the entire
genomes. Extent of homologies at nucleotide
level varies from 99% to 95% for the most
conserved genes located in the center of the
genome to approximately 75% for the most
divergent portions, located in the immediate-
early region. Major differences in biologic
properties concern the in vitro cell tropism,
regulation of transcription and splicing patterns,
reactivity to some MAbs directed to variant-
specific epitopes (29,34,35). Typically, variant A
viruses replicate in HSB-2 cells, whereas the
variant B viruses grow in the less differentiated
Molt3 T-cell lines. Variant B viruses grow to
higher yields than variant A viruses in primary
human fetal astrocytes and require IL-2- and
phytohemagglutinin-activated PBMCs. Differ-
ences between the two variants affect the
regulation of transcription of some ORFs of the
immediate early region-B and-A (U16, U17, U91)
and the splicing pattern of ORFs U18-U20 (37).
The differences relative to infection in humans
(epidemiology, correlation with pathologic fea-
tures, tissue tropism) are detailed below and in
the table.
All strains fall into one or the other variant
group. There is no evidence of recombination or a
genetic gradient, which suggests that in vivo the
two groups of viruses occupy different ecologic
niches. Any isolate characterized for more than
one marker has been unambiguously assigned to
one or the other variant group. The designation
of the two groups as variants has been highly
debated and controversial (38). A key question is
whether the two variants fulfill the criteria
defined by the International Committee on
Taxonomy of Viruses for classification as
different species (13). In our opinion, the
information summarized above indicates that
the two variant groups may be different species;
therefore, the issue of nomenclature should be
reconsidered.
Natural History of HHV-6 Infection
Infection with HHV-6 is very common,
approaching 100% in seroprevalence. Excep-
tions, if confirmed, are represented by countries
(e.g., Morocco) where seroprevalence is much
lower (20%) (39). Antibody titers are high in
newborn children, drop at 3 to 9 months after
birth, rise again briefly thereafter, and remain
elevated until the age of 60 or older. This pattern
indicates that newborns carry maternal antibod-
ies and primary infection occurs in the first 3
years of life, most frequently the first year.
Transplacental infections are very infrequent
but may contribute to HHV-6 seropositivity in
newborns (40).
Three stages can be recognized in the
natural history of HHV-6 infection (Figure 2).
The first is represented by acute primary
infection in infants. The second occurs in healthy
children and adults; the virus replicates in the
salivary glands and is secreted in saliva (for
HHV-6B) without inducing any obvious pathol-
ogy, remains latent at least in lymphocytes and
monocytes, and persists in various tissues,
possibly with a low-level replication. The third
stage occurs infrequently, typically in
immunocompromised persons, and is linked to
reactivation of virus from latency or reinfection.
Table. Epidemiology and distribution of human
herpesvirus (HHV-6) variants
Variant A Variant B
Associated pathologic
  conditions
  Exanthem subitum,   _a ++++
     febrile syndromesb
  Multiple sclerosis  ++   ++
  Lymphomas and neoplasies  ++   ++
  Reactivation in transplants  ++   ++
  Reactivation in AIDS  ++   ++
Tissue distribution
  Peripheral blood   +  +++
     mononuclear cells
  Salivary glands   _ ++++
  Skin  ++   ++
  Brain  ++   ++
  Lymph nodes   _ ++++
  Other tissues   _ ++++
  Serum from healthy persons   _    _
  Serum from exanthem   _ ++++
     subitum patients
  Serum from other patientsc +++    +
  Saliva   _ ++++
  Cerebrospinal fluid +++    +
aDifferent degrees of HHV-6 positivity.
bException, Zambian children, 44% variant A.
cPatients with AIDS, chronic fatigue syndrome, and
lymphomas.356 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Other pathologic conditions, mainly multiple
sclerosis, tumors, and CFS have been linked to
HHV-6.
Primary Infection
The unequivocal demonstration that pri-
mary infection with HHV-6B causes roseola
infantum was provided by Yamanishi et al. (8),
who investigated the correlation between
seroconversion to HHV-6B and childhood
infectious diseases and found that seroconversion
occurs concomitantly with roseola infantum, also
designated exanthem subitum or sixth disease, a
common, mild, acute febrile disease of infants.
Fever lasts for a few days and is sometimes
followed by a maculopapular rash that resolves
spontaneously. Primary infection may be
asymptomatic or may cause clinical manifesta-
tions other than classic exanthem subitum. In
four studies, children admitted to emergency
clinics with febrile illnesses were HHV-6-
positive in approximately 10% to 15% of cases
and in one study in approximately 45% of cases,
as determined by viral isolation, seroconversion,
or detection of viral DNA sequences in PBMCs.
Other than rash, symptoms included otitis,
gastrointestinal or respiratory distress, and
seizures (41-44). Complications of primary
HHV-6 infections are uncommon and rarely
fatal; they were described mainly as case reports
and include invasion of the central nervous
system (CNS) with seizures, hyperpyrexia,
vomiting, diarrhea, cough, emophagocytic syn-
drome, fulminant hepatitis, disseminated infec-
tion, and hepatosplenomegaly. These complica-
tions suggest that the virus may spread to a
number of organs, which may represent
potential sites of virus persistence or latency and
(subsequently) reactivation. For example, sei-
zures and other CNS complications are clear
indications of invasion of this organ and
correlate well with neurotropism of HHV-6.
Figure 2. Stages of the natural history of HHV-6 infection: I. Primary infection occurs in infants, may result in
exanthem subitum (rash on the childs chest), and spreads to organs. Question marks denote sites where HHV-6
spread is likely but not proven. II. In healthy infants and adults, HHV-6 is present in a latent or persistent form
in lymph nodes and is produced asymptomatically in salivary glands and shed in saliva, the most probable route
of transmission. III. HHV-6 infection/reactivation occurs in persons undergoing therapeutic immunosuppres-
sion after organ transplant or in AIDS patients.357 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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HHV-6 primary infection accounts for 10% to
45% of cases in children admitted to emergency
clinics with febrile illness and 1% of cases in
hospitalized children (42).
HHV-6B is not the only causative agent of
exanthem subitum. Occasionally, HHV-7 may
also cause fever with or without rash. Primary
infection with HHV-7 occurs at a somewhat later
age than with HHV-6B. Initially, it was proposed
that pathologic manifestations seen during
primary HHV-7 infection were the consequence
of HHV-6 reactivation by HHV-7. Evidence that
HHV-7 by itself causes an exanthematic disease,
although less frequently than HHV-6B, rests on
the finding that children with exanthem
subitum seroconvert to HHV-7 but remain HHV-
6B-negative (45,46).
Virus replicated in the salivary glands and
secreted in saliva is the epidemiologically proven
source of transmission. Other routes of
transmission have been suggested but remain to
be proven. HHV-6B DNA was recovered from
cervical tissues and secretions (47-49), but
children born to mothers with positive cervical
swabs did not acquire the infection. Intrauterine
transmission was suggested by polymerase chain
reaction (PCR) positivity of uncultured cord
blood mononuclear cells (CBMCs) in 1.6% of the
cases and by a case of abortion of an HHV-6-
positive fetus (40). Transmission through
breastfeeding is also doubtful since HHV-6 DNA,
unlike HHV-7, is not found in breast milk (50).
Integration of the HHV-6 genome in lympho-
blasts from a leukemic patient and his offspring
raised the possibility of genetic transmission. As
vertical transmission was not observed in other
cases of genome integration, the presence of
HHV-6 DNA in offspring was alternatively
interpreted as a tendency of HHV-6 to integrate
at specific chromosomal loci (51,52).
With the exception of a strong association of
HHV-6A with febrile syndromes in Zambian
children (43), which could reflect an endemic
variant A hot spot, HHV-6A has rarely been
isolated or detected in children with primary
HHV-6 infection (53,54). The age at which
primary HHV-6A infection occurs and the
diseases clearly linked to it have not been
determined.
HHV-6 in Healthy Persons
The second stage of HHV-6 infection occurs
in healthy children and adults, in whom the
virus actively replicates in the salivary glands, is
latent in at least lymphocytes and monocytes,
and persists in various tissues. Replication in
salivary glandsobserved for HHV-6B but not
HHV-6A (9,10,47)accounts for the route of
transmission and for the high frequency of
detection and isolation of virus in saliva.
Lymphocytes, and probably monocytes, repre-
sent two known sites of latency, as the virus can
be reactivated from PBMCs and adherent
monocytes upon cultivation (55), and viral DNA
sequences are detected in PBMCs of as much as
90% of the population. Additional sites of latency
likely exist since the virus or viral sequences can
be readily detected in a number of tissues. A form
of latent infection is represented by integration
of the HHV-6 genome in the host chromosomes
(51,52). Persistence of HHV-6 in cells and tissues
is discussed in the section In Vivo Tropism.
A missing link in our understanding of the
natural history of HHV-6 infection is the source
of the virus that spreads to organs. Monocytes
have a short half-life; they may be vehicles of
virus spread to organs, but they themselves need
to be infected. A possible source may be virus
produced in the salivary glands. In one case,
early bone marrow progenitor cells were found to
be latently infected in vivo (56), which raises the
possibility that they may represent a site of
latency, and by corollary, upon viral reactivation
from latency, an alternative source by which
virus spreads to tissues.
In immunocompetent adults, infection or
reactivation of HHV-6 at sites other than the
salivary glands is rare. Occasionally, infection
results in lymphoadenopathy, fulminant hepati-
tis, mononucleosislike syndrome, or generalized
infection.
HHV-6 in the Immunosuppressed
The third stage of HHV-6 infection, which
occurs in the immunosuppressed, is responsible
for the most serious clinical manifestations
associated with HHV-6 infection or reactivation.
Persons at risk are recipients of bone marrow,
kidney, and liver transplants, in whom
immunosuppression is induced for therapeutic
reasons. In these patients, HHV-6 infection or
reactivation may result in bone marrow
suppression, pneumonitis, encephalitis, en-
cephalopathy, hepatitis, fever, and skin rash or
may complicate engraftment of the transplanted
organ and culminate in rejection and death. As358 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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the number of persons undergoing organ
transplantation and, consequently, subjected to
therapeutic immunosuppression increases, the
number of persons at risk is increasing.
Assessment of the contribution of HHV-6 to
posttransplant complications is made more
difficult by the presence of other opportunistic
viruses and by the scarcity of thorough studies
on all the viruses present in these organs. Thus,
most of the reports on the presence of HHV-6 did
not deal with the fact that HCMV reactivation is
frequent in transplant recipients (particularly
kidney) and may occur together with HHV-6
reactivation. When investigated in detail, a
synergistic effect of HHV-6 and HCMV was
apparent in renal transplant recipients, and the
simultaneous detection of both HHV-6 and
HCMV DNAs in urine or serum or of
immunoglobulin (Ig) M antibodies was the
strongest predictor of viral disease and of
severity of disease (57,58). HHV-7 can also
reactivate in transplant recipients (59), again
alone and in association with HHV-6 or HCMV.
Each of these viruses is a pathogen in its own
right, and in combination with the other, may
produce disease far more serious in outcome and
clinical manifestations than it would alone. In
many studies, no effort was made to identify the
HHV-6 variant. When the variants were
characterized, a rather heterogeneous pattern
emerged. In PBMCs, brain and lungs variant B
strains were predominant (60-62), whereas in
spinal fluid and serum, variant A strains were
prevalent (63,64). In approximately 30% of bone
marrow transplant recipients in whom pneu-
monitis developed, both variants were simulta-
neously detected (62), an otherwise rare
occurrence.
AIDS patients are the second group of
immunocompromised persons at risk for HHV-6
and HCMV-related opportunistic viral infec-
tions. The overall incidence of these infections
has decreased substantially after the introduc-
tion of highly active antiretroviral therapy.
HHV-6 infection/reactivation in AIDS patients
results in an increase in HHV-6 load both in
lymph nodes and generalized, in viremia,
disseminated infection in many organs, active
CNS infection, pneumonitis, and retinitis and
may contribute as a cause of death (65-67). These
findings lead to the proposal that HHV-6 acts as
a cofactor in the progression of AIDS and in the
switch of HIV from the latent to the replicative
state (68). Although a significant increase in
HHV-6 viral load was not observed in PBMCs of
HIV-seropositive persons (68,69), HHV-6 and
HIV could interact in lymph nodes. The
possibility that HHV-6 acts as a cofactor in AIDS
progression boosted intense research on mutual
interactions between HHV-6 and HIV in cell
cultures and cell-free systems. In addition to
coinfection, observed in vivo and in vitro, HHV-6
promotes HIV replication through upregulation
of cytokines (e.g., TNF-a  and IL-1ß) and through
transactivation of the long terminal repeat by
IE-A and IE-B (68). The possibility that in vivo
HHV-6 infection may lead to HIV reactivation
was examined recently in HIV-positive children.
The children in whom AIDS progressed rapidly
acquired primary HHV-6 infection later than
those in whom HIV progressed slowly; however,
in the rapid progress to AIDS the HIV viral load
did not increase at the outcome of HHV-6
infection. Late in AIDS, HHV-6 detection in
PBMCs is reduced, most likely because of T-cell
depletion (69). As a rule, the variant A strains are
more frequently associated with AIDS patients.
In Vivo Tissue Distribution
In addition to the salivary glands, HHV-6
has been frequently isolated from cultured
PBMCs from AIDS patients or children with
exanthem subitum or febrile illnesses. This led to
the initial definition of HHV-6 as a lymphotropic
virus. In lymphocytes, the virus establishes a
latent infection, readily monitored by PCR
amplification of viral DNA sequences in
uncultured PBMCs (47). Furthermore, produc-
tive infection has been monitored in some cases
by immunohistochemistry (e.g., in CD4+
T lymphocytes) (70). In contrast with the earlier
view of HHV-6 as a T-lymphotropic virus, recent
investigations detected HHV-6 in many tissues.
Despite the wealth of research on the presence of
HHV-6 in humans, our knowledge is fragmen-
tary. By immunohistochemical staining, active
HHV-6 infection was detected in various cells
(e.g., CD68+ cells of the monocyte/macrophage
lineage in Kaposi sarcoma [71], epithelial cells
and lung macrophages, dendritic cells and
macrophages of lymph nodes and infiltrating
lymphocytes of organs of unselected patients
who died of AIDS, tubular epithelial cells of
kidney) and in submandibular glands (67,72).
Consistent with this wider host range, HHV-6
DNA sequences were detected in a number of359 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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organs (e.g., skin, spleen, lung, heart, kidney,
adrenal gland, esophagus, duodenum, colon,
liver, and early bone marrow progenitor cells)
from patients who died of heart attack or
accidents (47,56,65). Since in numerous studies
detection was performed by PCR, latent,
persistent, or productive infections were not
differentiated, nor was the nature of the infected
cells defined. Variant B strains are more
frequently found in both PBMCs and solid
tissues. Variant A viruses appear predominant
in skin and can replicate in primary fibroblast
cultures, suggesting a preferential tropism for
skin (47). HHV-6 is a brain commensal (see
section entitled Neurotropism and Multiple
Sclerosis).
In Vitro Tropism
In vitro, HHV-6 infects and replicates at
highest titers in PBMCs and CBMCs. In these
heterogeneous cultures, susceptible cells are the
CD4+ T lymphocytes but also the CD4-
CD3+CD8+ and the CD4-CD3- natural killer
cells (68). Inasmuch as CD4 expression is not a
requirement for susceptibility to HHV-6 infec-
tion and soluble forms of CD4 and antibodies to
CD4 fail to inhibit virus infectivity (73), CD4 is
not a necessary component of the cellular
receptor for HHV-6. In addition to primary T
lymphocytes, T-lymphocytic lines (e.g., HSB-2,
SupT1, Molt3, JJhan, MT-4, ET62) support
HHV-6 growth. Viruses of the two variants
display different host range, as variant A strains
generally do not replicate in Molt3 cells, whereas
variant B strains do not replicate in HSB-2 cells.
Permissive cells of lineages other than
T lymphocytes are the liver cell line HepG2 (74)
and a number of human and nonhuman cell lines
in which the virus generally grows at very low
yields (e.g., cervical cells lines, human primary
astrocytes [B variant does not replicate very
well] neuroblastoma, human bowel-derived cell
monocytes, megakaryocytes endothelial cells,
NBL-7 mink lung epithelial cells, and PBMCs of
several Macaca species) (75-77). Altogether, in
cell cultures as well as in vivo, HHV-6 appears to
have a host range wider than initially
recognized, extending beyond T lymphocytes.
While this is meaningful with respect to studies
on the natural history of the infection, the
practical use of these cells in the laboratory is
hampered by the very low virus yields. Even in
the most permissive systems (PBMCs, CBMCs,
and T-cell lines), the virus yields are very low. In
our experience, CBMC cultures, the most
productive cell type, do not yield more that 104
infectious units per ml, whereas the titer of a
herpes simplex virus type 1 stock is generally as
high as 109- 1010 plaque-forming units per ml.
Neurotropism and Multiple Sclerosis
HHV-6 is probably the most neurotropic
virus known. Neuroinvasion has been docu-
mented in infants with primary infection, in
focal encephalitis, in children and adults with
AIDS, in recipients of bone marrow transplants,
as well as in immunologically competent
children and adults. Challoner et al. (78)
reported viral DNA sequences in approximately
two thirds of brain specimens and viral antigen
expression in a number of cell types (e.g.,
astrocytes, macrophages, epithelial cells, endot-
helial cells of blood vessels) at very similar
frequencies in specimens from healthy persons
and multiple sclerosis patients. Astrocytes were
confirmed as a susceptible cell population,
although in a subsequent study only samples
from AIDS patients were positive (79).
Both variant viruses were detected in the
brain of patients who died of causes related or
unrelated to HHV-6, which demonstrates that
both variant viruses can invade and be harbored
in the brain (61,78-82). Although studies on the
differential distribution of the two variant
groups provided conflicting results (78,83), for
HHV-6B, CNS invasion has been documented at
primary infection. Instead, for HHV-6A, the time
of CNS invasion has not been documented.
A possible correlation between active HHV-6
infection and multiple sclerosis has been the
focus of much attention in the past few years.
Multiple sclerosis is a severe CNS disease of
young adults, characterized by the progressive
demyelination of nerves that leads to progressive
paralysis and eventually death. The disease
appears to be an autoimmune reaction to myelin,
the coating of nerve fibers. Viruses have long
been suggested as etiologic agents of myelopa-
thies, and DNA sequences from a number of
viruses, particularly herpesviruses, have been
detected, although not consistently. In addition,
since multiple sclerosis is accompanied by a
characteristic increase in IgG titer in serum and
spinal fluid, antibodies to various viruses
(including HHV-6) have been frequently searched
for. Even immunologic studies have been360 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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inconclusive, most probably because the increase
in antibody response reflects an immune
dysfunction or different genetic background
together with damage of the blood-brain barrier,
rather than an epidemiologic correlation with
any given virus.
Studies of HHV-6 infection or reactivation in
multiple sclerosis patients have provided
controversial results. In initial reports, active
infection was suggested by an increase in IgG
titer in both serum and spinal fluid but was not
confirmed by increase in PCR positivity of
PBMCs (84). By representational difference
PCR, Challoner et al. (78) found that multiple
sclerosis specimens contained HHV-6B DNA
sequences. HHV-6B antigen expression was
detected at higher frequency in multiple
sclerosis plaques than in histologically normal
specimens. Nuclei of oligodendrocytes were
positive in multiple sclerosis samples (80%) but
not in control samples (0%) and were interpreted
as a hallmark of the association between active
or reactivable HHV-6 infection and the disease.
Attempts to reproduce the immunohistochemi-
cal results were not successful, and viral
expression as documented by reverse tran-
scriptase (RT)-PCR was also negative (85). In
favor of a correlation are subsequent findings
that the frequency and titer of anti-HHV-6 IgM
antibodies are higher in samples from multiple
sclerosis patients than from controls (73% vs.
18%) and that the serum DNAemia was
specifically positive in multiple sclerosis patients
(30% vs. 0%) (86). HHV-6 DNA sequences had
been detected in spinal fluid, but not in serum
from multiple sclerosis patients (87). Critical
interpretation of these data can be summarized
as follows. The serologic analyses are difficult to
interpret as this disease is characterized by an
immunologic dysregulation; therefore, the in-
crease in antibody titer may be a sign of the
disease rather than a cause. The PCR data were
not confirmed. Thus, no statistical difference was
reported in DNA positivity of plaques (32% active
vs. 17% inactive plaques) (88), no DNA was
detected in serum and cerebrospinal fluid
samples (89-91), and no viral RNA was found by
RT-PCR in multiple sclerosis brain specimens
(85). The differences in PCR results may reflect
differences in PCR conditions (e.g., primers,
number of cycles, characteristics of the amplified
sequences, nature, and conservation of the
specimens analyzed) but do not account for the
observed discrepancies. Therefore, correlation
between active HHV-6 infection and multiple
sclerosis is still a controversial issue rather than
a firmly established conclusion.
Kaposi Sarcoma
Kaposi sarcoma is a multifocal angioprolifera-
tive disease localized predominantly in the skin
or mucous membranes and in other visceral
organs and lymph nodes. In addition to the
classic, iatrogenic, and endemic forms, the
disease occurs frequently and aggressively in
AIDS patients. Human herpesvirus 8 (HHV-8)
sequences were detected for the first time in
Kaposi sarcoma specimens (92,93) by represen-
tational difference analysis PCR; HHV-8 is being
investigated as the possible etiologic agent.
Epidemiologic studies had long suggested a viral
etiology, and many viruses, including HHV-6
and HHV-7, were detected in Kaposi sarcoma
tissues. While neither HHV-6 nor HHV-7
appears to contribute to its etiology, Kaposi
sarcoma represents a unique and interesting
environment for these viruses, and they may
have a role in the progression of the tumor. By
immunohistochemistry, HHV-6B has been
localized to CD68+ cells of the monocytic
macrophage lineage. These cells are either singly
infected with HHV-6 or HHV-7 or doubly
infected with HHV-6 and HHV-7 (Figure 3) (71).
Although some tissues harbor both viruses,
albeit in different cells (e.g., lungs and salivary
glands), cells doubly infected with HHV-6 and
HHV-7 have not been detected in any tissue
other than Kaposi sarcoma lesions (94). In
addition, in the case of HHV-7, CD68+ cells are a
cell type infected, singly or doubly, in no other
tissue but in this tumor (71). Data suggest that
the particular microenvironment of Kaposi
sarcoma lesions, which is rich in chemokines and
cytokines, attracts circulating lymphocytes and
monocytes that harbor HHV-6 and HHV-7 in a
latent or persistent form, induces viral
reactivation, and promotes viral growth. In this
peculiar environment two unusual situations
occur. Viral yields are high for both HHV-6 and
HHV-7. This accounts for the likelihood of double
HHV-6 and HHV-7 infection, which most likely
appears to take place in the tumor itself. HHV-7
tropism is also not restricted to T lymphocytes
and extends to CD68+ cells, a lineage not
susceptible to HHV-7 infection in other tissues. A
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may contribute to dysregulating cellular chemok-
ine expression or signaling. In addition, the virus
expresses its own chemokine receptors encoded
by the U12, and possibly U51 genes. Once HHV-
6 is reactivated and actively replicating, HHV-6
may play a role in tumor progression through
these molecules and mechanisms. Different
studies detected different variant strains in
Kaposi sarcoma tumors (95,96). The reason for
this discrepancy is unknown.
Lymphoproliferative and Neoplastic
Disorders
Initial isolation of HHV-6 from patients with
lymphoproliferative disorders boosted studies on
possible association of HHV-6 with proliferative
diseases, particularly of lymphoid origin, aimed
at showing either a transforming potential of the
virus in cell cultures or epidemiologic and
molecular relationships between HHV-6 and
various types of neoplasia.
In favor of a possible oncogenic potential is
the transforming ability of three viral DNA
fragments on mouse fibroblast cell lines or
human epidermal keratinocytes. One encodes
DR7 (97) and the other two encompass the
regions spanning U2-U20 and U31-U37. The
derived cellular clones were malignant and
tumorigenic in athymic mice (98,99). DR7 and the
two other loci also contain genes with
transactivating activity on the HIV LTR.
Clinical and molecular investigations deal-
ing with HHV-6 and various types of tumors
have been reviewed (13). The overall importance
of these findings remains controversial, mainly
because the criteria for establishing an
association between the virus and its oncogenic
potential have not been met. Thus, the viral DNA
sequences found in a tumor are expected to be
the same as those with in vitro transforming
potential, and in vitro-transformed cells should
be tumorigenic in animals. In a given type of
tumor the viral sequences should constantly be
the same. In vitro-transformed cells and tumors
should express the same viral gene products. The
oncogenic potential of the virus should be
demonstrated in a suitable animal model (which
is lacking for HHV-6). Chromosomal integration
of HHV-6 DNA in cells from lymphomas (51,52)
may open a new scenario.
CFS
CFS is an illness characterized by memory
and attention impairment, muscle and multijoint
pain, and unrefreshing sleep and weakness
lasting longer than 6 months. The etiology of the
disease is unknown, and many viruses have been
investigated as possible causing agents. The
overall scenario is in a way similar to that of
multiple sclerosis. Serologic analysis on the
presence of antibody to HHV-6 provided
inconclusive data. An increase in IgG and IgM
Figure 3. Expression of human herpesvirus 6B (HHV-6B) and HHV-7 antigens in serial sections of Kaposi
sarcoma specimens. Panels A-C: In Kaposi sarcoma environment, cells can be doubly infected by HHV-6B and
HHV-7: (A) Staining with monoclonal antibody 5E1 to HHV-7-specific antigen pp85; (B) Staining with
monoclonal antibody to HHV-6B-specific antigen p101; (C) Overlaid serial sections show colocalization of HHV-
6B and HHV-7 (71).362 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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titer in the sera of a large number of CFS
patients (119 of 154) was found relative to that in
the control population (77% vs. 12%) (100).
However, this was not specific, as an increase in
antibodies to other viruses was also detected,
reflecting probably an immunologic dysfunction.
Molecular analysis showed a higher prevalence
of HHV-6A but not HHV-6B or HHV-7 in CFS
patients (64,101,102), and HHV-6A could also be
isolated from these patients (103). Whether this
reflects an association or the consequence of an
immune dysregulation remains to be deter-
mined.
Conclusions
The epidemiologic and clinical investigations
summarized here establish a clear correlation
between HHV-6B primary infection and exan-
them subitum and between HHV-6 infection/
reactivation and a number of pathologic
conditions in immunocompromised patients and
transplant recipients. A firm correlation with
other diseases remains doubtful. In the case of
multiple sclerosis a clearly established correla-
tion may identify patients who might benefit
from specific anti-HHV-6 chemotherapy.
Yet another area deserving attention is the
state of the virus in healthy people, a key
prerequisite to understanding virus behavior in
pathologic conditions. We have underlined that,
in addition to establishing the true latent
infection recognized in earlier studies, HHV-6
persists in the host through a combination of low-
level persistent infection of various cells and
tissues, a situation similar to that reported
recently for HHV-7 (94). Sites of latency may
represent a reservoir of the virus, which upon
reactivation may feed the sites of persistency.
The pathogenic mechanisms of HHV-6 at the
molecular, cellular, and tissue level remain
largely obscure. Almost 10 years elapsed
between the first isolation of HHV-6 and
publication of the sequence of the entire genome.
Now, single gene products can be studied in the
context of the viral genome and in heterologous
expression systems. Although a system for
mutagenesis of the viral genome has yet to be
developed, the stage is set to ask questions on the
molecular mechanisms underlying pathogenic-
ity of the virus. The forthcoming area of research
will probably focus on links between the function
of single gene products and mechanisms of
pathogenesis and virus spread. A key feature of
the HHV-6 life-style in the human host is its
ability to infect and survivein a latent or
persistent formin the cells of the immune
system, and the pathogenic potential of HHV-6 is
linked to its ability to evade immune system
control. Analysis of the genomic sequence shows
candidates for immune evasion strategies.
Yamanishi and colleagues reported that a 7-
transmembrane protein encoded by U12 acts as a
ß-chemokine receptor (26). As ß-chemokines are
key mediators of the immune response, the
ß-chemokine receptor may subtract these
mediators in a particular microenvironment.
The immune evasion strategy must be more
complex, as analysis of the viral DNA sequence
shows additional candidates, e.g., a predicted
chemokine encoded by ORF U83 and a second
7-transmembrane proteina structural feature
typical of chemokine receptorsencoded by ORF
U51. This latter protein has a very unusual cell-
type-dependent trafficking property (as it is
transported to the plasma membrane in infected
as well as transfected T lymphocytes) but fails to
be transported to the plasma membrane in
transfected human monolayer cells (104), raising
the possibility that its function is regulated in a
cell-dependent fashion through modulation of
cell surface expression. Also U51 appears to
dysregulate cellular chemokine expression (105).
Studies of single gene products will probably lead
to the identification of immunodominant
proteins and the development of standardized
recombinant diagnostic reagents.
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